Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Immune System Diseases (2)
- Amino Acids, Peptides, and Proteins (1)
- Anatomy (1)
- Biological Phenomena, Cell Phenomena, and Immunity (1)
- Chemicals and Drugs (1)
-
- Hemic and Immune Systems (1)
- Immunity (1)
- Immunology and Infectious Disease (1)
- Life Sciences (1)
- Medical Immunology (1)
- Medical Pharmacology (1)
- Medical Sciences (1)
- Medical Specialties (1)
- Medical Toxicology (1)
- Medicinal Chemistry and Pharmaceutics (1)
- Oncology (1)
- Other Chemicals and Drugs (1)
- Otorhinolaryngologic Diseases (1)
- Pharmaceutics and Drug Design (1)
- Pharmacology (1)
- Pharmacology, Toxicology and Environmental Health (1)
- Pharmacy and Pharmaceutical Sciences (1)
- Respiratory Tract Diseases (1)
- Skin and Connective Tissue Diseases (1)
- Toxicology (1)
- Translational Medical Research (1)
- Virus Diseases (1)
- File Type
Articles 1 - 3 of 3
Full-Text Articles in Diseases
Avaren-Fc, A Novel Immunotherapeutic, Recruits Nk Cells In B16f10 Melanoma Tumor Tissue, Sreevatsa Vemuri, Katarina Mayer, Nobuyuki Matoba
Avaren-Fc, A Novel Immunotherapeutic, Recruits Nk Cells In B16f10 Melanoma Tumor Tissue, Sreevatsa Vemuri, Katarina Mayer, Nobuyuki Matoba
Posters-at-the-Capitol
Melanoma is the fifth most common cancer in the US, with limited effective immunotherapeutic options available for patients. Avaren-Fc (AvFc) is a novel experimental immunotherapeutic agent with a unique “lectibody” property. It is capable of targeting cancer cells through the selective recognition of high mannose glycans, which are aberrantly overrepresented on the surface of malignant cells. AvFc can interact with circulating effector immune cells equipped with Fc receptors, such as natural killer (NK) cells to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and kill cancer cells. Previous work has shown that AvFc effectively induces ADCC activity against B16F10 cancer cells in vitro …
Phase 1a Clinical Study For Q-Griffithsin Intranasal Spray For Prevention Of Coronavirus, Megan Bezold, Kenneth Palmer, Nobuyuki Matoba, Elizabeth Cash
Phase 1a Clinical Study For Q-Griffithsin Intranasal Spray For Prevention Of Coronavirus, Megan Bezold, Kenneth Palmer, Nobuyuki Matoba, Elizabeth Cash
Posters-at-the-Capitol
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible virus that causes acute respiratory disease with possible long-term complications, known as coronavirus disease 2019 (COVID-19). Griffithsin (GRFT; including the oxidation-resistant variant Q-GRFT used in this study) is an algal carbohydrate-binding protein exhibiting antiviral effects against many enveloped viruses, including all major variants of SARS- CoV-2 reported to date. Q-GRFT has been recombinantly manufactured in Nicotiana benthamiana plants, thoroughly purified, and formulated as an intranasal spray designed to be developed as a non-vaccine broad-spectrum prophylactic product for acute use. This is the first-in-human, randomized, double-blind, placebo-controlled study. The …
L-Serine Reduces Reactive Oxygen Species Yield In Cisplatin Treated Zebrafish Utricles, Satya A. Moolani, Elvin Irihamye, Jerry D. Monroe, Michael E. Smith
L-Serine Reduces Reactive Oxygen Species Yield In Cisplatin Treated Zebrafish Utricles, Satya A. Moolani, Elvin Irihamye, Jerry D. Monroe, Michael E. Smith
Posters-at-the-Capitol
Cisplatin is a chemotherapy compound effective against a variety of cancers. However, it can act as an ototoxin and cause hearing loss by promoting reactive oxygen species (ROS) production in auditory tissues. The antioxidant amino acid, L-serine has been hypothesized to lower levels of cisplatin-mediated ROS. In this project, we investigated whether L-serine can reduce cisplatin-mediated ROS production in auditory tissue and potentially act as an otoprotectant during cisplatin chemotherapy. We used a zebrafish utricular tissue culture system and fluorescent ROS indicator dye to spectrophotometrically measure if L-serine could decrease reactive oxygen species levels in cisplatin-treated tissues. We found that …